✦ LIBER ✦

The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate

✍ Scribed by Sung-Eun Lee; Soo Young Choi; Ju-Hee Bang; Soo-Hyun Kim; Eun-jung Jang; Ji-Young Byeun; Jin Eok Park; Hye-Rim Jeon; Yun Jeong Oh; Myungshin Kim; Dong-Wook Kim

Book ID: 119211557
Publisher: Elsevier
Year: 2012
Tongue: English
Weight: 436 KB
Volume: 205
Category: Article
ISSN: 2210-7762
DOI: 10.1016/j.cancergen.2012.09.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clonal chromosomal abnormalities in the

Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib

✍ Guilbert-Douet, N; Morel, F; Bris, M-J Le; Berthou, C; Morice, P; Bourquard, P; 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 83 KB

Imatinib mesylate therapy improves survi

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase : Comparison with historic data

✍ Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Francis J. Giles; Mary Beth Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## BACKGROUND The International Randomized study of Interferon‐alpha plus cytarabine (IFN‐α plus ara‐C) versus STI571 (imatinib mesylate) [IRIS trial] in patients with newly diagnosed Philadelphia chromosome (Ph)‐positive, chronic‐phase chronic myelogenous leukemia (CML) has not shown

Long-term prognostic impact of the use o

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

✍ Fabio P. S. Santos; Yesid Alvarado; Hagop Kantarjian; Dushyant Verma; Susan O'Br 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 1 views

Long-term safety and efficacy of imatini

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

✍ Philippe Rousselot; Pascale Cony-Makhoul; Franck Nicolini; François Xavier Mahon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

PCN92 Cost-Effectiveness of Nilotinib Ve

PCN92 Cost-Effectiveness of Nilotinib Versus Imatinib as First-Line Treatment for Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Russian Federation

✍ R. Yagudina; A. Kulikov; I. Komarov 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Significance of suboptimal response to i

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during